<p><span style="color:#231F20;"><strong><u>BENIGN PROSTATIC HYPERPLASIA</u></strong></span></p><p style="margin-left:0cm;text-align:justify;"><span style="color:#231F20;">Benign Prostatic Hyperplasia (BPH) refers&nbsp;to non-cancerous enlargement of the prostate gland which results in obstruction of urine flow from the bladder. BPH is the commonest cause of male urinary symptoms in Ghana. The average age at which lower urinary tract symptoms (LUTS) related to BPH occurs is about 50 years. Men may seek treatment&nbsp;for&nbsp;LUTS&nbsp;either&nbsp;because the&nbsp;symptoms&nbsp;are&nbsp;bothersome&nbsp;or&nbsp;they feel that it may lead to acute urinary retention or out of fear that it may be an indication of prostate&nbsp;cancer.</span> <span style="color:#231F20;">It is important to establish what the patient wants from the consultation. In some patients, once reassured that the likelihood of urinary&nbsp;retention&nbsp;and&nbsp;prostate cancer&nbsp;is&nbsp;low,&nbsp;they&nbsp;may&nbsp;not&nbsp;wish&nbsp;treatment. for the symptoms.</span> <span style="color:#231F20;">Currently available medicines can either relax prostatic smooth muscles or cause reduction in the prostate size and therefore ease the symptoms of BPH. A combination of available medications, especially in patients with a prostate size more than 40 ml, produce better responses than monotherapy.</span> <span style="color:#231F20;">BPH may lead to complications such as recurrent urinary tract infection, acute urine retention with painful distension of the bladder, chronic urine retention with painless gross distension of the bladder, haematuria, and renal failure.</span></p><p>&nbsp;</p><h3 style="margin-left:0cm;">CAUSES</h3><ul><li>Increase&nbsp;in&nbsp;number&nbsp;of&nbsp;prostate&nbsp;cells&nbsp;due&nbsp;to&nbsp;stimulation&nbsp;by testosterone</li></ul><h3 style="margin-left:0cm;">SYMPTOMS</h3><ul><li>Lower&nbsp;Urinary Tract&nbsp;Symptoms&nbsp;(previously&nbsp;referred to&nbsp;as&nbsp;prostatism)</li><li>Hesitancy&nbsp;-&nbsp;delay&nbsp;in&nbsp;initiating&nbsp;urination</li><li>Poor or weak urinary&nbsp;stream</li><li>Straining</li><li>Terminal&nbsp;dribbling</li><li>Sensation of incomplete bladder&nbsp;emptying</li><li>Urinary incontinence (overflow) or&nbsp;bedwetting</li><li>Frequent&nbsp;passage of&nbsp;urine&nbsp;especially&nbsp;at&nbsp;night&nbsp;(Nocturia)</li><li>Urgency and urge&nbsp;incontinence</li></ul><h3 style="margin-left:0cm;">SIGNS</h3><ul><li>Enlarged&nbsp;prostate gland&nbsp;on&nbsp;rectal examination</li><li>Tender&nbsp;palpable&nbsp;bladder(acute&nbsp;urinary&nbsp;retention)</li><li>Non-tender palpable bladder (chronic&nbsp;retention)</li><li>Uraemia&nbsp;signs&nbsp;(e.g.&nbsp;drowsiness,&nbsp;confusion&nbsp;etc.)</li><li>Palpable kidneys in&nbsp;hydronephrosis</li></ul><h3 style="margin-left:0cm;">INVESTIGATIONS</h3><ul><li>Serum&nbsp;creatinine</li><li>Prostate&nbsp;specific antigen&nbsp;(PSA)&nbsp;-&nbsp;to&nbsp;exclude prostate&nbsp;cancer</li><li>Urine for culture and&nbsp;sensitivity</li><li>Abdominal&nbsp;and&nbsp;pelvic&nbsp;ultrasound&nbsp;-&nbsp;to&nbsp;exclude hydronephrosis&nbsp;if serum creatinine is&nbsp;elevated</li></ul><h3 style="margin-left:0cm;">TREATMENT</h3><p><strong>Treatment objectives</strong></p><ul><li>To exclude prostate cancer and reassure patients&nbsp;accordingly</li><li>To&nbsp;relieve&nbsp;symptoms and&nbsp;prevent&nbsp;development&nbsp;of&nbsp;complications</li><li>To identify and treat any associated&nbsp;complications</li></ul><h3 style="margin-left:0cm;">Non-pharmacological treatment</h3><ul><li>Programme of monitoring and watchful waiting through regular check-ups for mild&nbsp;symptoms</li><li style="text-align:justify;">Urethral catheterization for acute retention of urine or suprapubic cystostomy if urethral catheterization fails</li><li style="text-align:justify;">Suprapubic needle puncture and aspiration/drainage of urine to partially&nbsp;decompress&nbsp;the&nbsp;bladder and&nbsp;relieve&nbsp;pain, when&nbsp;suprapubic cystostomy is&nbsp;delayed.</li></ul><h3 style="margin-left:0cm;text-align:justify;">Pharmacological&nbsp;treatment</h3><ol><li style="text-align:justify;"><span style="color:#231F20;"><strong>Patients&nbsp;with&nbsp;bothersome&nbsp;symptoms&nbsp;and&nbsp;prostate size&nbsp;less&nbsp;than 40 ml (small&nbsp;prostate)</strong></span></li></ol><p style="margin-left:0cm;text-align:justify;"><span style="color:#231F20;">1<sup>st</sup> Line Treatment Evidence Rating: [A]</span></p><ul><li style="text-align:justify;">Terazosin,&nbsp;oral, 2-10 mg at night, (start with 2 mg at night; double&nbsp; dose at weekly intervals) max. 10&nbsp;mg.</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Tamsulosin, oral, 400 microgram once&nbsp;daily</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Alfuzosin, oral, 10 mg&nbsp;daily</li></ul><ol><li><span style="color:#231F20;">Patients&nbsp;with&nbsp;bothersome&nbsp;symptoms and&nbsp;prostate&nbsp;size&nbsp;more&nbsp;than 40 ml (big&nbsp;prostate)</span></li></ol><p style="margin-left:0cm;"><span style="color:#231F20;">Evidence Rating: [A]</span></p><ul><li>Finasteride, 5 mg&nbsp;daily</li></ul><h3 style="margin-left:0cm;">And</h3><ul><li>Terazosin,&nbsp;oral, 2-10 mg at night, (start with 2 mg at night; double dose at weekly intervals) max. 10&nbsp;mg.</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Tamsulosin, oral, 400 microgram&nbsp;daily</li></ul><h3 style="margin-left:0cm;">Or</h3><ul><li>Alfuzosin, oral, 10 mg&nbsp;daily</li></ul><p>&nbsp;</p><h3 style="margin-left:0cm;text-align:justify;">REFERRAL CRITERIA</h3><p style="margin-left:0cm;text-align:justify;"><span style="color:#231F20;">Refer&nbsp;patients who don't respond to pharmacological treatment,&nbsp; or have complications (urine retention, haematuria, renal failure and recurrent&nbsp;urinary&nbsp;tract&nbsp;infection)&nbsp;to&nbsp;a&nbsp;Urologist or&nbsp;Surgical&nbsp;specialist.</span></p>